[Concentration of 14C-1-butylbiguanide in plasma of diabetic patients and its elimination after administration of a new Galenical formulation (author's transl)].
The time course of 1-butylbiguanide concentration in plasma and the urinary and fecal elimination of the substance were measured in six female elimination of the substance were measured in six female diabetic patients after oral administration of 100 mg of 14C-1-butylibiguanide hydrochloride as Sindiatil. The mean maximum plasma concentration was 37 mug/100 ml and was reached after about 2 1/2 h. At least semi-maximum plasma concentrations (greater than or equal 18 mug/100 ml) were maintained between the 1st and 8th h after administration. Within 24 h 64% of the administered dose were eliminated (36% via the kidneys, 28% with the faeces). After 3 days a total of 80% had been eliminated, one-half each in urine and faeces, respectively. The average time taken for 50% of maximum renal elimination, and thus of the absorbed quantity, to be excreted was 7.2 h.
D000368:Aged; D001645:Biguanides / Q000097:blood*; D002026:Buformin / Q000008:administration & dosage / Q000097:blood*; D003692:Delayed-Action Preparations; D003920:Diabetes Mellitus / Q000097:blood*; D005260:Female; D006801:Humans; D007700:Kinetics; D008875:Middle Aged
D001645:Biguanides; D003692:Delayed-Action Preparations; D002026:Buformin
Plasmakonznetration und Elimination von 14C-1-Butyl-biguanid-HCl bei Diabetikern nach Einnahme der Substanz in einer neuen Zubereitung